



## INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NUMBER YPL-0057 SERIAL NUMBER 10/608,709 FILED 6-27-2003  
FIRST INVENTOR: Il Hwan Cho TITLE 1, 2, 4-TRIAZOLE DERIVATIVE,  
METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION  
CONTAINING THE SAME EXAMINER NYA ART UNIT NYA

- Applicant submits herewith a copy of (a) attached form PTO-1449, which lists all patents, publications, applications, or other information submitted for consideration by the Office; (b) a legible copy of each document required by 37 C.F.R. §1.98(b)(2).
- Applicant herein apprises the Patent Office of references cited in a parent U.S. application from which this application obtains the benefit of an earlier filing date under 35 U.S.C. §120. The Serial Number of the parent application is U.S. Application \_\_\_\_\_  
The publications cited therein are listed on attached Form PTO-1449. In accordance with 37 C.F.R. §1.98(d) copies of the listed publications are not required.  Additional parent patent applications are listed on an attached sheet.
- In accordance with 37 C.F.R. §1.98(a)(3), Applicant hereby certifies that for each reference not in English (check at least one box below):  
 A copy of a translation of one or more non-English document, or portion thereof, is provided herewith;  
 A concise explanation is (check at least one box below):  
 provided in the accompanying foreign or international search report;  incorporated into the specification; and/or  provided herewith.

### 37 C.F.R. §1.97(b)(1), (b)(2) – WITHIN 3 MONTHS OF FILING OR ENTRY IN NATIONAL STAGE

- Since this Information Disclosure Statement is being filed within three months of the filing date of the subject application or within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application, no fee or certification under 37 C.F.R. §1.97(e) is required.

### 37 C.F.R. §1.97(b)(3), (b)(4) – PRIOR TO MAILING OF FIRST OFFICE ACTION OR FIRST ACTION AFTER REQUEST FOR CONTINUED EXAMINATION

- Since this Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits, or before the mailing date of a first Office action after the filing of a request for continued examination under 37 C.F.R. §1.114, no fee or certification under 37 C.F.R. §1.97(e) is required.

### 37 C.F.R. §1.97(c) – AFTER FIRST ACTION, BEFORE FINAL ACTION OR ALLOWANCE

- Since this Information Disclosure Statement is being filed outside of the period provided for in 37 C.F.R. §1.97(b), but before the mailing date of a Final Rejection or Notice of Allowance, this submission is being accompanied by (one of the following boxes must be checked):
  - the fee required under 37 C.F.R. §1.97(c)(2) and specified in 37 C.F.R. §1.17(p).
  - the statement specified in 37 C.F.R. §1.97(e) (Box 8 or 9 must be checked).

### 37 C.F.R. §1.97(d) – AFTER FINAL REJECTION OR ALLOWANCE

- Since this Information Disclosure Statement is being filed after the period specified in 37 C.F.R. §1.97(c), but on or before payment of the issue fee and is accompanied by both the statement specified in 37 C.F.R. §1.97(e) and the fee set forth in 37 C.F.R. §1.17(p). (Box 8 or 9 must be checked.)
- In accordance with 37 C.F.R. §1.97(e)(1), Applicant's attorney certifies that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.  The foreign or international search report(s) is/are enclosed.
- In accordance with 37 C.F.R. §1.97(e)(2), Applicant's attorney certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this certification after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of the information disclosure statement.
- In the event the Commissioner of Patents deems that any additional fee is required under 37 C.F.R. §§ 1.16 or 1.17 in connection with this application, Applicant's attorneys authorize that such fee be charged to Deposit Account No. 06-1130.


11. Consideration of this Information Disclosure Statement is respectfully requested.

Name:	<b>Soonja Bae</b>	
Signature		
	Registration Number	<b>SEE ATTACHED</b>
	Date	<b>September 17, 2003</b>

**CERTIFICATE OF MAILING OR TRANSMISSION:** I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or [ ] facsimile transmitted to the U.S. Patent and Trademark Office to Facsimile No. \_\_\_\_\_ on the date shown below.

Name:	<b>Tammie Lanthier</b>	
Signature		
	Date	<b>September 17, 2003</b>





**INFORMATION DISCLOSURE CITATION**  
*(Use several sheets if necessary)*

(Use several sheets if necessary)

SEP 22 2003

Docket Number (Optional) **YPL-0057**

Application Number

**Applicant(s)**

**Filing Date**

### Group Art Unit

NYA

## U.S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO
	95/00501	1-15-1995	PCT				
	EP 1 104 759 A1	6-6-2001	EUROPE				

**OTHER DOCUMENTS** *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	<p>"Current Perspective Recent advances in the management of colorectal cancer"; Authors: E. Van Cutsem, M. Dicato, J. Wils; European Journal of Cancer 37; Elsevier Science Ltd.; 2001; Pgs. 2302-2309</p>
	<p>Monthly Focus: Central &amp; Peripheral Nervous Systems; "Anti-inflammatory drugs: a hope for Alzheimer's disease?"; Authors: Michael Hull, Klaus Lieb &amp; Bernd L. Fiebich; Asley Publications Ltd.; 2000; Pgs. 671-683</p>

**EXAMINER** \_\_\_\_\_ **DATE CONSIDERED** \_\_\_\_\_

**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

YPL-0057

Application Number

10/608,709

Applicant(s)

Il Hwan Cho, et al.

Filing Date

6-27-2003

Group Art Unit

NYA

\*EXAMINER

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

News and Views; "Towards a better aspirin"; Author: John Vane; Nature, Vol. 367; January 20, 1994; Pgs. 215-216

Meeting Report; "COX-1 and COX-2: Toward the Development of More Selective NSAIDs"; Authors: Bruno Battistini, Regina Botting and Y.S. Bakhle; DN &amp; P 7 (8); October 1994; Pgs. 501-512

Chapter 19; "Selective Cyclooxygenase Inhibitors"; Authors: David B. Reitz and Karen Seibert; Annual Reports in Medicinal Chemistry-30; Academic Press, Inc.; 1995; Pgs. 179-188

Pergamon; "Synthesis and Biological Evaluation of 2, 3-Diarylthiophenes as Selective COX-2 and COX-1 Inhibitors"; Authors: Yves Leblanc, Jacques Yves Gauthier, Diane Ethier, Jocelyne Guay, Joseph Mancini, Denis Riendeau, Philip Tagari, Philip Vichers, Elizabeth Wong and Petpiboon Prasit; Bioorganic &amp; Medicinal Chemistry Letters, Vol. 5, No. 18; Elsevier Science Ltd.; 1995; Pgs. 2123-2128

"Synthesis and Biological Evaluation of the 1, 5-Diarylpyrazole Class of Cyclooxygenase-2 Inhibitors: Identification of 4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] benzenesulfonamide (SC-58635, Celecoxib)"; Authors: Thomas D. Penning, et al.; Journal of Medicinal Chemistry Vol. 40, No. 9; American Chemical Society; 1997; Pgs. 1347-1365

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.